Drugs / NDV-3A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01926028 | Jul 2013 → May 2015 | vulvovaginal candidiasis | NovaDigm Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02996448 | Nov 2016 → Jul 2018 | hyper-IgE syndrome 6, autosomal dominant, with recurrent infections | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03455309 Comparator | Jan 2018 → Jul 2019 | staphylococcus aureus infection | NovaDigm Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NDV-3A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02996448 ↗ |
| Modality | Vaccine | “evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein” PMID 29697768 ↗ Jun 2018 |
| Route | Intramuscular | “1 intramuscular dose of NDV-3A was safe” PMID 29697768 ↗ Jun 2018 |